Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200358 | 0.83 | MAPT (0.36) | KDM4EMAPTL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL5418077 | 0.82 | ALDH1A1 (0.51) | KDM4EMAPTL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL5422529 | 0.78 | KDM4E (0.47) | KDM4EMAPTL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL30020347 | 0.71 | KDM4E (0.83) | KDM4EMAPTL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL28744296 | 0.70 | KDM4E (0.59) | KDM4EMAPTL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL5422453 | 0.70 | ALDH1A1 (0.50) | KDM4EMAPTL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL24039431 | 0.69 | DNMT1 (0.43) | MAPTL3MBTL1TDP1SMN1; SMN2NPC1 | |
| SCHEMBL9537983 | 0.69 | KDM4E (0.74) | KDM4EMAPTL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL9536822 | 0.69 | KDM4E (0.70) | KDM4EMAPTL3MBTL1TDP1SMN1; SMN2 | |
| SCHEMBL6018669 | 0.68 | MAPK14 (0.65) | KDM4EMAPTL3MBTL1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262309-B2 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | GLAXOSMITH KLINE ISTRAZIVOCKI CENTAR ZAGREB, D.O.O. (HR) | 2007-08-28 | — | — | US | claimed |
| US-20070173499-A1 | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2007-07-26 | — | — | US | claimed |
| EP-1708696-A1 | USE OF BENZONAPHTHOAZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2006-10-11 | — | — | EP | claimed |
| EP-1492795-B1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2005-11-16 | — | — | EP | claimed |
| WO-2005072728-A1 | USE OF BENZONAPHTHOAZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2005-08-11 | — | — | WO | claimed |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.D.D. (HR) | 2005-06-23 | — | — | US | claimed |
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | claimed |
| EP-1492795-A1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2005-01-05 | — | — | EP | claimed |
| WO-2003084961-A1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2003-10-16 | — | — | WO | claimed |
| US-7262309-B2 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | GLAXOSMITH KLINE ISTRAZIVOCKI CENTAR ZAGREB, D.O.O. (HR) | 2007-08-28 | — | — | US | disclosed |
| US-20070173499-A1 | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2007-07-26 | — | — | US | disclosed |
| EP-1492795-B1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2005-11-16 | — | — | EP | disclosed |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.D.D. (HR) | 2005-06-23 | — | — | US | disclosed |
| EP-1492795-A1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084961-A1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | KDM4E 2670/4885MAPT 1058/4885L3MBTL1 2008/4885 |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | KDM4E 2986/4885MAPT 1241/4885L3MBTL1 1739/4885 |
| US-20070173499-A1 | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | BCHE, GAP43, DBH | KDM4E 1637/4885MAPT 110/4885L3MBTL1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.